

BORIS-forskning





Karolinska
Institutet

Steatotic liver disease and increased risk of youth-onset type 2 diabetes

Full article:



Resthie R Putri, Thomas Casswall, Pernilla Danielsson Liljeqvist,
Claude Marcus, Emilia Hagman

Popular summary:



Outline

- **What did we study?**
- Why this study is important
- How BORIS and Swedish registers were excellent sources for this study
- Main findings
 - The effect of fatty liver disease (MASLD) on type 2 diabetes
 - Response of paediatric obesity treatment
- Summary




Does metabolic dysfunction
associated steatotic liver disease
(MASLD) increase the risk of
youth-onset type 2 diabetes in
children with obesity?

Outline


- What did we study?
- **Why this study is important**
- How BORIS and Swedish registers were excellent sources for this study
- Main findings
 - The effect of fatty liver disease (MASLD) on type 2 diabetes
 - Response of paediatric obesity treatment
- Summary

MASLD, one of the most common morbidity in children with obesity



Ref: Sharma V, Obes Rev, 2019

Metabolic dysfunction associated steatotic liver disease (MASLD) in children



- Previous name: non-alcoholic fatty liver disease.
- Main drivers: obesity & insulin resistance.
- Clinically silent in most cases.
- No approved pharmacological treatment for children yet.

Image from: Mann JP, Archives of Disease in Childhood, 2015

Diseases associated with MASLD in adults



Cirrhosis and liver cancer



Chronic kidney disease



Type 2 diabetes



Cardiovascular disease



Hypertension

Ref: Chan KE, Clinical Gastroenterology and Hepatology, 2024

Diseases associated with MASLD in ~~adults~~ children



Cirrhosis and liver cancer



Chronic kidney disease



Type 2 diabetes



Cardiovascular disease



Hypertension



Ref: Chan KE, Clinical Gastroenterology and Hepatology, 2024



MASLD in children has been hypothesised to have worse outcomes than adult MASLD.



The previous studies were limited.


- Small sample size, short follow-up
- From people joining military service

Outline

- What did we study?
- Why this study is important
- **How BORIS and Swedish registers were excellent sources for this study**
- Main findings
 - The effect of fatty liver disease (MASLD) on type 2 diabetes
 - Response of paediatric obesity treatment
- Summary



BORIS
Barnobesitas Registret i Sverige





PERSONNUMMER






Children
undergoing
obesity
treatment



Children undergoing obesity treatment



MASLD


No MASLD

Follow-up from age 9 up to 30 years



Type 2 diabetes

General population: same birth year, sex, residential area




Follow-up from age 9 up to 30 years



Outline

- What did we study?
- Why this study is important
- How BORIS and Swedish registers were excellent sources for this study
- **Main findings**
 - The effect of fatty liver disease (MASLD) on type 2 diabetes
 - Response of paediatric obesity treatment
- Summary

Children with obesity and MASLD had the greatest incidence of type 2 diabetes



Higher degree of
obesity?

Elevated fasting
glucose?

Parental type 2
diabetes?

MASLD in paediatric obesity is associated with 2.7 times higher risk of youth-onset type 2 diabetes.

Hazard ratio	Age 9 – 30 y	Age 9 – 19 y	Age 20 – 30 y
No MASLD	Ref	Ref	Ref
MASLD	2.71 (2.14 – 3.43)**	3.99(2.99 – 5.32)**	1.28 (0.79 – 2.07)

Adjusted for sex, age, degree of obesity, intermediate hyperglycaemia at baseline, parental type 2 diabetes


* P < 0.05, ** p < 0.001



MASLD vs intermediate hyperglycaemia on the risk of type 2 diabetes

Intermediate hyperglycaemia/ prediabetes:
fasting glucose 6.1–6.9 mmol/L or HbA1c 39–46 mmol/mol

The presence of both MASLD and intermediate hyperglycaemia increase the risk of type 2 diabetes dramatically





BMI reduction of at least 0.25 SDS (median treatment: 17.3 months) was associated with **77% relative risk reduction** of type 2 diabetes, regardless of MASLD, HR = 0.23 (0.09–0.57).

Outline

- What did we study?
- Why this study is important
- How BORIS and Swedish registers were excellent sources for this study
- Main findings
 - The effect of fatty liver disease (MASLD) on type 2 diabetes
 - Response of paediatric obesity treatment
- **Summary**

- MASLD in paediatric obesity is associated with 2.7 times higher risk of youth-onset type 2 diabetes.
- The risk is dramatically higher if MASLD and intermediate hyperglycaemia are present at baseline.
- Optimal obesity treatment response reduced type 2 diabetes risk by 77%, regardless of MASLD.

Full article:



- Liver and glucose screening should both be a regular part of obesity management.
- A decrease in the degree of obesity in paediatric years is essential to prevent youth-onset type 2 diabetes

Popular summary:









Karolinska
Institutet

Mer BORIS-forskning

Barnobesitas och risk för multipel skleros

Preliminära resultat

Riskfaktorer för MS



Tidigare forskning

- Hög BMI i ung ålder beräknas bidra till mer än 10% av alla MS-fall.
- Det har föreslagits att associationen mellan tidig obesitas och MS endast gäller för obesitas i ungdomsåren och inte i barndomen.

Vårt syfte: att jämföra risken för MS hos barn och ungdomar i BORIS med en matchad kontrollgrupp från den generella populationen.

*Pakpoor J, et al. Int J Epidemiol 2021; Hedstrom AK, et al. Mult Scler 2016;
Olsson T, et al. Nat Rev Neurol 2017;*

Kohort-studie



BORIS

n = 21 652



Median (Q1, Q3) uppföljningstid
5.6 (3.0, 9.6) år



MS diagnos
Emigration
Död
Augusti 2023

Gernerella populationen

n = 102 187



Kopplingen mellan obesitas och MS

- Långvarig låggradig inflammation
- Kost och tarmflora
- Delad genetisk sårbarhet – osannolikt
- Obesitas-duration?
- Blir det en additiv effekt av obesitas och kända riskfaktorer, ex vitamin D-brist?

Annan BORIS-forskning

Hur används BORIS för forskning?

- Studier inom BORIS
- Kontrollgrupper från BORIS
- BORIS länkat till andra register eller kohorter

- Etiskt tillstånd krävs
- Personnummer lämnas inte ut till enskild forskare

Kvalitets- och förbättringsarbete på mottagningen kräver inget etiskt tillstånd. Vi kan hjälpa till med enklare arbete.

ARTICLE

Response of Severely Obese Children and Adolescents to Behavioral Treatment

Pernilla Danielsson, RN, PhD; Jan Kowalski, BA; Örjan Ekblom, PhD; Claude Marcus, MD, PhD

International Journal of Obesity (2019) 43:1988–1994
<https://doi.org/10.1038/s41366-019-0384-2>

ARTICLE**Pediatrics**

The effect of weight loss and weight gain on blood pressure in children and adolescents with obesity

Emilia Hagman¹ · Pernilla Danielsson¹ · Amira Elmagam¹ · Claude Marcus¹

ORIGINAL ARTICLE

Impaired fasting glucose prevalence in two nationwide cohorts of obese children and adolescents

E Hagman^{1,5}, T Reinehr^{2,5}, J Kowalski¹, A Ekblom³, C Marcus^{1,6} and RW Holl^{4,6}

ORIGINAL RESEARCH

FATIGUE
OBESITY

WILEY

Paediatric obesity treatment during 14 years in Sweden: Lessons from the Swedish Childhood Obesity Treatment Register—BORIS

Emilia Hagman¹ | Pernilla Danielsson¹ | Louise Lindberg¹ | Claude Marcus¹ | on behalf of the BORIS Steering Committee

Karolinska Institutet – ett medicinskt universitet

Laparoscopic Roux-en-Y gastric bypass in adolescents with severe obesity (AMOS): a prospective, 5-year, Swedish nationwide study

Torsten Olbers, Andrew J Beamish, Eva Gronowitz, Carl-Erik Flodmark, Jovanna Dahlgren, Gustaf Bruze, Kerstin Ekblom, Peter Friberg, Gunnar Götthorn, Kaisa Häyölä, Jon Karlsson, Staffan Mårlind, Martin Neovius, Markus Paltonen, Claude Marcus

The Journal of Clinical Endocrinology & Metabolism, 2023, 00, 1–7

<https://doi.org/10.1210/clinem/dgad419>

Advance access publication 15 July 2023

Clinical Research Article



Height and Growth Velocity in Children and Adolescents Undergoing Obesity Treatment: A Prospective Cohort Study

Resthie R P

RESEARCH ARTICLE

Open Access

Anxiety and depression in children and adolescents with obesity: a nationwide study in Sweden

**RESEARCH ARTICLE**

Association of childhood obesity with risk of early all-cause and cause-specific mortality: A Swedish prospective cohort study

Louise Lindberg^{1*}, Pernilla Danielsson¹, Martina Persson^{2,3,4}, Claude Marcus¹, Emilia Hagman¹

Tack vare er så lär vi oss mer om
barnobesitas!

Acknowledgments

The authors would like to thank all the pediatric obesity treatment units for their contribution to the BORIS register.



**Karolinska
Institutet**